Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly EBITDA Margin of 9267.68% in Q3 2025, up 43.75% quarter-over-quarter from 16477.2% in Q2 2025, and down 814171.0% on a YoY basis from N/an in Q3 2024.
Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 9267.68% for Q3 2025.
- In Q3 2025, EBITDA Margin fell 814171.0% year-over-year to 9267.68%; the TTM figure through Sep 2025 stood at 4072.65% (down 282791.0% YoY), while the FY2024 annual figure was 1361.83%, up 17204.0% from the prior year.
- EBITDA Margin was 9267.68% for Q3 2025 at Dianthus Therapeutics, up from 16477.2% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 676.39% in Q3 2022 to a low of 16477.2% in Q2 2025.
- Historically, EBITDA Margin has averaged 3251.27% across 4 years, with a median of 1581.46% in 2024.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 51270 bps in 2024, then tumbled 1553158 bps in 2025.
- A 4-year view of EBITDA Margin shows it stood at 874.53% in 2022, then sank by 182 bps to 2467.61% in 2023, then gained by 11 bps to 2188.16% in 2024, then tumbled by 324 bps to 9267.68% in 2025.
- The last three EBITDA Margin figures came in at 9267.68% (Q3 2025), 16477.2% (Q2 2025), and 2445.58% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -9,267.68% |
| Jun 30, 2025 | -16,477.20% |
| Mar 31, 2025 | -2,445.58% |
| Dec 31, 2024 | -2,188.16% |
| Sep 30, 2024 | -1,125.97% |
| Jun 30, 2024 | -945.63% |
| Mar 31, 2024 | -1,581.46% |
| Dec 31, 2023 | -2,467.61% |
| Sep 30, 2023 | -1,638.67% |
| Jun 30, 2023 | -1,110.20% |
| Mar 31, 2023 | -1,467.44% |
| Dec 31, 2022 | -874.53% |
| Sep 30, 2022 | -676.39% |